Novo Nordisk 'B'

From September 1, distribution of the first orally available GLP‑1 tablet Wegovy (semaglutide) begins in Germany. Approval in tablet form was granted in July; the prescription requirement remains in place and pharmacies are expected to be stocked if supply is sufficient. Doctors and pharmacists stress the importance of targeted counseling on use, side effects and target groups; the drug is approved for obesity or overweight with at least one weight‑related comorbidity. Novo Nordisk is aiming for further growth in Europe after the successful launch in the US. » More on deraktionaer.de

Novo Nordisk is launching the Wegovy pill for obesity in Germany; demand and preorders are high and doctors are running waiting lists. Studies show about 17% weight loss with the pill, while Eli Lilly’s injection Mounjaro achieves up to 20% and the company plans its own pill, Foundayo. The drugs are expected not to be reimbursed by insurers; the market is seen as lucrative because of the high prevalence of obesity and strong growth expectations. Competition between Novo Nordisk and Eli Lilly is likely to remain intense as more players enter the market and technical developments continue. » More on wiwo.de

The Novo Nordisk share briefly recovered on Friday after Deutsche Bank cut its rating to sell and lowered the price target to DKK 265, but slid back into negative territory during trading. The rebound is supported by the acceptance of the approval application for the Wegovy tablet in China, which is significant in the race for oral weight-loss drugs. Analysts remain divided: recommendations range from sell to hold, with price targets between DKK 200 and DKK 332. The focus remains on approval progress in China and market dynamics in the diabetes and obesity segments. » More on finanzen.net